

Technology Advisory Committee A Interests Register
Avelumab for treating metastatic Merkel cell carcinoma [ID1617]
Publication Date: 21/04/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Steve Edwards	TA Committee A Member	Non-financial professional & personal interest	Member of the Evidence Review Group for this appraisal.	NA	07/01/2021	NA	It was agreed that this declaration would prevent Dr Edwards from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
Dr Paul Nathan	Clinical Expert	Direct - financial	Received compensation for advisory board, speaker's bureau membership and institutional research funding for several companies, unrelated to this application.	NA	12/02/2020	NA	It was agreed these declarations would not prevent Dr Nathan from providing expert advice to the committee.
Dr Paul Nathan	Clinical Expert	Direct - financial	Advisory boards for Merck and Pfizer. These advisory boards were not relevant to this application.	NA	02/02/2021	NA	It was agreed this declaration would not prevent Dr Nathan from providing expert advice to the committee.
Ms Nicola Jervis	Patient Expert	Indirect Interest	Ms Jervis' employer, Neuroendocrine Cancer UK,	NA	02/02/2021	NA	It was agreed this declaration would not prevent Ms Jervis from

			received an unrestricted grant to produce leaflets.				providing expert advice to the committee.
--	--	--	---	--	--	--	---